1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A.

Authors :: Gadgeel, S.M.
Mok, T.S.K.
Peters, S.
Nadal, E.
Han, J-Y.
Alatorre Alexander, J.A.
Leighl, N.
Sriuranpong, V.
Pérol, M.
Castro, G.D.
de Marinis, F.
Tan, D.S.W.
Paul, S.
Assaf, Z.J.
MacLennan, M.
Lohmann, T.O.
Slade, M.
Mathisen, M.S.
Bhagawati-Prasad, V.
Dziadziuszko, R.
Source :: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS782-S783. 2p.
Publication Year :: 2023

Subjects :: *CIRCULATING tumor DNA
*NON-small-cell lung carcinoma
*BIOMARKERS
*DNA
*TUMORS

Full Text Access

Tools